{"id":113694,"date":"2025-07-28T08:12:00","date_gmt":"2025-07-28T11:12:00","guid":{"rendered":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/releases\/releases-geral\/boehringer-ingelheim-and-re-vana-therapeutics-announce-strategic-collaboration-to-develop-long-acting-ophthalmic-therapies\/"},"modified":"2025-07-28T08:12:00","modified_gmt":"2025-07-28T11:12:00","slug":"boehringer-ingelheim-and-re-vana-therapeutics-announce-strategic-collaboration-to-develop-long-acting-ophthalmic-therapies","status":"publish","type":"post","link":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/releases\/releases-geral\/boehringer-ingelheim-and-re-vana-therapeutics-announce-strategic-collaboration-to-develop-long-acting-ophthalmic-therapies\/","title":{"rendered":"Boehringer Ingelheim and Re-Vana Therapeutics Announce Strategic Collaboration to Develop Long-Acting Ophthalmic Therapies"},"content":{"rendered":"

\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Up to three development programs per year leading to a potential total deal value exceeding $1 billion contingent on milestone achievements.<\/b><\/p>\n

Ingelheim, Germany, Tampa, Florida, USA, and Belfast, Northern Ireland, UK [28 July 2025] <\/b>Boehringer Ingelheim and Re-Vana Therapeutics, a US and UK based developer of ocular therapeutics and ocular drug delivery technologies, today announced a strategic collaboration and license agreement that aims to develop first-in-class extended-release therapies for eye diseases.<\/p>\n

Globally, millions of people living with eye health conditions face a progressive decline in their independence and connection to the world due to vision loss. With its diverse pipeline in eye health, which includes four assets in Phase II, Boehringer Ingelheim is committed to preserving the retina, protecting peoples way of life and preventing vision loss. Treating ophthalmic diseases often requires frequent injections directly into the eye, which can be very burdensome for patients. Re-Vanas drug delivery technology is designed to release treatments slowly over six to 12 months, aiming to drastically reduce how often patients need injections. Lowering the treatment burden could lead to higher treatment compliance, and potentially result in better therapeutic outcomes. Boehringer Ingelheim will explore combining this technology with its unique pipeline in eye health.<\/p>\n

Were looking forward to team up with Re-Vana to push the boundaries of whats possible in eye health, said Nedim Pipic, Global Head of Mental Health, Eye Health and Emerging Areas at Boehringer Ingelheim. Together, we want to tackle the limits of todays treatments aiming to help people keep their sight, with fewer injections. This partnership is a bold step forward in our mission to protect vision and ease the burden on patients.\u00a0<\/p>\n

The strategic collaboration with Boehringer Ingelheim marks a transformational moment for Re-Vana, said Michael ORourke, Re-Vana Chief Executive Officer. By combining our extended-release platform with Boehringer Ingelheims world-class research and development capabilities and eye health pipeline, we strive to bring forward a new generation of long-acting treatments for eye diseases that offer clinical and quality-of-life benefits for patients.<\/p>\n

Under the collaboration, Boehringer Ingelheim aims to add up to three projects per year across therapeutic modalities. The companies will jointly oversee Re-Vanas feasibility and development activities for the extended-release programs, with Boehringer Ingelheim assuming sole responsibility for clinical development, regulatory approval, and global commercialization of the products. The terms of the agreement grant Boehringer Ingelheim target exclusivity, and provide for upfront, development, regulatory and commercial milestone payments to Re-Vana, with total potential deal value exceeding $1 billion for the initial three targets, in addition to royalty payments on net sales.\u00a0\u00a0<\/p>\n

Boehringer Ingelheim<\/b><\/p>\n

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industrys top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain.\u00a0Our approximately 54,500 employees serve over 130\u00a0markets to\u00a0build a healthier and more sustainable tomorrow. Learn more athttps:\/\/www.boehringer-ingelheim.com<\/a> (Global) or https:\/\/www.boehringer-ingelheim.com\/uk<\/a>(UK). \u00a0<\/b><\/p>\n

About\u00a0Re-Vana Therapeutics<\/b><\/p>\n

Re-Vana Therapeutics Ltd, founded in 2016 as a spin-out from Queens University Belfast, is an ocular therapeutics and innovative ocular drug delivery company based in Belfast, Northern Ireland, and a wholly owned subsidiary of Re-Vana Holding, Inc., Tampa, Florida.\u00a0<\/p>\n

Re-Vana is venture backed with leading US Ophthalmic investors including Visionary Ventures, ExSight Ventures, InFocus Capital Partners and UK investors including QUBIS, TechStart Ventures, Invest Northern Ireland and Clarendon Fund Managers. Re-Vana is currently raising a Series B round for their sustained release anti-VEGF asset.\u00a0 Learn more at https:\/\/www.revanatx.com\/<\/a><\/p>\n

Intended Audiences Notice<\/b><\/p>\n

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.<\/p>\n

Media Contacts\u00a0<\/u><\/b><\/p>\n

\u00a0<\/u><\/b><\/p>\n

Boehringer Ingelheim:\u00a0
Dr. Reinhard Malin<\/b>
Boehringer Ingelheim Corporate Center GmbH\u00a0
Innovation Unit\/Bio Comms, Corp. Affairs\u00a0
Media + PR\u00a0
press@boehringer-ingelheim.com<\/a><\/p>\n

Linda Ruckel
<\/b>Boehringer Ingelheim
Innovation Unit Communications
Linda.ruckel@boehringer-Ingelheim.com<\/a><\/p>\n

\u00a0<\/b><\/p>\n

Re-Vana:<\/b><\/p>\n

Michele Gray<\/b>\u00a0
Gray Communications, LLC
Michele@mgraycommunications.com
<\/b>+1 917 449 9250<\/p>\n

\"\"
\"\"
\n\"Primary<\/a><\/p>\n

A OESP<\/b> nao e(sao) responsavel(is) por erros, incorrecoes, atrasos ou quaisquer decisoes tomadas por seus clientes com base nos Conteudos ora disponibilizados, bem como tais Conteudos nao representam a opiniao da OESP<\/b> e sao de inteira responsabilidade da GlobeNewswire<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Up to three development programs per year leading to a potential total deal value exceeding $1 billion contingent on milestone achievements.\nIngelhe","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[34],"tags":[],"class_list":["post-113694","post","type-post","status-publish","format-standard","hentry","category-releases-geral"],"acf":[],"_links":{"self":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts\/113694","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/comments?post=113694"}],"version-history":[{"count":0,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts\/113694\/revisions"}],"wp:attachment":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/media?parent=113694"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/categories?post=113694"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/tags?post=113694"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}